CHOK1-GenS&CHOK1-ADCC+
Cell Line Development System Commercial License

High productivity with CHOK1-GenS system

• Suitable for different type of molecules
  
  

  

Excellent stability with CHOK1-GenS system

• No.	Type	Study period	T1（g/L)	Titer variation
  1	IgG 1	PCB-60days	3.43	-9.90%
  2	IgG 1	PCB-60days	3.54	-7.00%
  3	IgG 4	PCB-50days	3.15	-9.00%
  4	IgG 4	PCB-60days	3.63	-8.20%
  5	IgG 4	PCB-60days	4.23	-10.40%
  6	Bispecific mab	PCB-60days	2.72	-3.40%
  7	IgG 1	PCB-60days	4.68	-22.22%
  8	IgG 1	PCB-96days	4.76	-23.39%
  9	Protein	PCB-50days	1.91	-11.52%
  10	IgG 1	PCB-60days	6.37	-4.55%
  11	tri-specific ab	PCB-50days	0.34	-17.60%
  12	IgG 1	WCB-50days	3.78	-24.60%
  13	IgG 1	WCB-50days	5.74	-20.55%

• • The titer at the end of stability study during fed-batch is recorded as T2.
  • The titer at the beginning of stability study during fed-batch is recorded as T1.
  • Titer variation=(T2-T1)/T1*100%
  • Titer variation should be within 30%.
  Contact us

High productivity with CHOK1-GenS system

• Titer prior to cell culture up to 15 g/L

  
  Contact us

• Excellent Stability in Scale-Up from 3L to 200L

  • 
  • 
  • 
  • 

• CD16a 158V/F affinity (BLI)

  
  • The affinity to CD16a (158V and 158F) was increased by 3-4 times.

• PBMC-based ADCC

  
  • Cytotoxicity is increased by about 10%.
  • Effect concentration (EC50) was reduced by 6 times.
  • ADCC effect was significantly enhanced.